

## Measure Description

The percentage of members 40-75 years of age during 2024 with diabetes, who do not have clinical atherosclerotic cardiovascular disease (ASCVD) and met the following criteria:

1. **Received Statin Therapy:** Members who were dispensed at least **one** statin medication of any intensity during 2024.
2. **Statin Adherence 80%:** Members who achieved a proportion of days covered (PDC) of at least 80% of the treatment period on a statin medication of any intensity during 2024.

Members with diabetes are identified by claim/encounter and pharmacy data during 2023 or 2024.

---

## Definitions

**Index Prescription Start Date (IPSD):** The earliest prescription dispensing date for any statin medication of any intensity during 2024.

**Treatment Period:** The period beginning on the IPSD through December 31, 2024.

**Proportion of Days Covered (PDC):** The number of days the Member is covered by at least one statin medication prescription of appropriate intensity, divided by the number of days in the treatment period.

- Calculating number of days covered for multiple prescriptions:
    - Multiple prescriptions for different medications dispensed on the same day: calculate the number of days covered by a statin using the prescription with the longest days' supply.
    - Multiple different prescriptions dispensed on different days with overlapping days: count each day in the treatment period only once.
    - Multiple prescriptions for the same medication dispensed on the same day or on different days – add the days' supply and use the total to calculate the number of days covered by a statin medication. Subtract any day's supply that extends beyond December 31, 2024.
-

Follow the steps below to calculate the PDC:	
<b>Step 1</b>	Identify the IPSD (the earliest dispensing event for any intensity statin medication during 2024.)
<b>Step 2</b>	Determine the treatment period; calculate the number of days beginning on the IPSD through December 31, 2024.
<b>Step 3</b>	Count the days covered by at least one prescription for any intensity statin medication during the treatment period. Subtract any day's supply that extends beyond December 31, 2024.
<b>Step 4</b>	<p>Calculate the PDC using the following equation:</p> $\frac{\text{Total Days Covered by a Statin Medication in the Treatment Period (Step 3)}}{\text{Total Days in Treatment Period (Step 2)}}$ <p>Convert to percentage by multiplying by 100 and round (using the 0.5 rule) to the nearest whole number.</p>
Statin medications:	
<b>High-Intensity Statin Therapy</b>	Atorvastatin 40-80mg, Amlodipine-atorvastatin 40-80mg, Rosuvastatin 20-40mg, Simvastatin 80mg, Ezetimibe-simvastatin 80mg
<b>Moderate-Intensity Statin Therapy</b>	Atorvastatin 10-20mg, Amlodipine-atorvastatin 10-20mg, Rosuvastatin 5-10mg, Simvastatin 20-40mg, Ezetimibe-simvastatin 20-40mg, Pravastatin 40-80mg, Lovastatin 40mg, Fluvastatin 40-80mg, Pitavastatin 1-4mg
<b>Low-Intensity Statin Therapy</b>	Ezetimibe-simvastatin 10mg; Fluvastatin 20mg; Lovastatin 10-20mg; Pravastatin 10-20mg; Simvastatin 5-10mg
The following will exclude Members from this measure:	
<b>Hospice Encounter During 2024</b>	<b>HCPCS:</b> G9473, G9474, G9475, G9476, G9477, G9478, G9479, Q5003, Q5004, Q5005, Q5006, Q5007, Q5008, Q5010, S9126, T2042, T2043, T2044, T2045, T2046
	<b>SNOMED:</b> 183919006, 183920000, 183921001, 305336008, 305911006, 385765002
	<b>UBREV:</b> 0115, 0125, 0135, 0145, 0155, 0235, 0650, 0651, 0652, 0655, 0656, 0657, 0658, 0659
<b>Hospice Intervention During 2024</b>	<b>CPT:</b> 99377, 99378
	<b>HCPCS:</b> G0182

	<b>SNOMED:</b> 170935008, 170936009, 385763009
<b>Palliative Care Assessment During 2024</b>	<b>SNOMED:</b> 718890006, 718893008, 718895001, 718898004, 718899007, 718901003, 718903000, 718904006, 718957007, 718967002, 718969004, 718971004, 718973001, 718974007, 718975008, 718976009, 761865002, 761866001, 761867005, 457511000124100
<b>Palliative Care Encounter During 2024</b>	<b>Palliative Care Encounter</b> <b>ICD10CM:</b> Z51.5 Do not include laboratory claims with POS code 81
	<b>HCPCS:</b> G9054, M1017
	<b>SNOMED:</b> 305284002, 305381007, 305686008, 305824005, 441874000, 713281006, 4901000124101
<b>Palliative Care Intervention During 2024</b>	<b>SNOMED:</b> 103735009, 105402000, 395669003, 395670002, 395694002, 395695001, 443761007, 1841000124106, 433181000124107

**Members with the following:**

1. Members with a diagnosis of pregnancy during 2023 or 2024. Do not include laboratory claims with POS code 81
2. Myocardial Infarction, CABG, PCI, and any other revascularization procedures during 2023
3. IVD in both 2023 and 2024
4. In Vitro Fertilization in 2023 or 2024
5. ESRD, Cirrhosis, Dialysis, in 2023 or 2024. For ESRD and Cirrhosis, do not include laboratory claims with POS code 81
6. Myalgia, Myositis, Myopathy, or Rhabdomyolysis in 2024. Do not include laboratory claims with POS code 81

**Patients who died any time during 2024**

## Tips and Best Practices to Help Improve Performance

- Include the following topics in your discussions with patients who are prescribed statin medications:
  - Importance of statin medication adherence and lifestyle modifications (diet, exercise, weight loss)
  - Side effects such as muscle pain and what to do if they occur
  - What to do about missed doses
  - Identify barriers that would impact adherence to statin therapy
- Once the patient demonstrates that they tolerate statin therapy, prescribe a 90-day supply
- Utilize the monthly Gaps in Care (GIC) Report for a list of MVP Members and the services they still need
- Consider using alerts and flags within the Electronic Health Record (EHR) for screening tests
- Discuss the importance of early detection and encourage preventive care
- Document preventive care, medical, and surgical history in the medical record with specific date and results
- Use correct diagnosis and procedure codes and submit claims and encounter data in a timely manner
- Stock patient areas and exam rooms with educational materials such as those found here:
  - [Diabetes | CDC](#)
  - [Medical Health - MVP Health Care](#)